| Detected | Trial | Change |
|---|---|---|
| 2026-06-03 | NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly… |
Trial completed |
| 2026-06-03 | NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly… |
date change Completion moved earlier: 2026-09-19 -> 2026-03-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With… | Ganglioneuroblastoma | Recruiting |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of… | Ganglioneuroblastoma, Nodular | Recruiting |
| Phase 2 | |||
| NCT07085338 | A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy… | Neuroblastoma Recurrent | Recruiting |
| NCT06450041 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb)… | Neuroblastoma | Recruiting |
| NCT03794349 | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in… | High Risk Neuroblastoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma | Relapsed Neuroblastoma | Recruiting |
| NCT07437963 | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come… | Recurrent Ganglioneuroblastoma | Not Yet Recruiting |
| Phase 1 | |||
| NCT02573896 | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | Neuroblastoma | Active, Not Recruiting |
| NCT01711554 | Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients… | Recurrent Neuroblastoma | Active, Not Recruiting |